Back to Search
Start Over
Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.
- Source :
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Jan; Vol. 67 (1), pp. e28010. Date of Electronic Publication: 2019 Sep 22. - Publication Year :
- 2020
-
Abstract
- Autoimmune cytopenias (AIC) following allogeneic hematopoietic stem cell transplantation (HSCT) may cause significant morbidity and mortality and are often challenging to treat. We present a case of a pediatric patient with primary myelofibrosis of infancy caused by VPS45 protein deficiency, who developed severe refractory hemolytic anemia and immune-mediated thrombocytopenia 3.5 months following HSCT. After the failure of several treatments, he received daratumumab, an anti-CD38 specific antibody, and demonstrated fast and sustained response. The only side effect was delayed recovery of humoral immunity. Daratumumab, by targeting antibody-producing plasma cells, may be a valid treatment option for refractory post-HSCT AIC.<br /> (© 2019 Wiley Periodicals, Inc.)
- Subjects :
- Anemia, Hemolytic etiology
Anemia, Hemolytic pathology
Anemia, Refractory etiology
Anemia, Refractory pathology
Child, Preschool
Humans
Male
Primary Myelofibrosis pathology
Prognosis
Transplantation, Homologous
Vesicular Transport Proteins deficiency
Anemia, Hemolytic drug therapy
Anemia, Refractory drug therapy
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Hematopoietic Stem Cell Transplantation adverse effects
Primary Myelofibrosis therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1545-5017
- Volume :
- 67
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Pediatric blood & cancer
- Publication Type :
- Academic Journal
- Accession number :
- 31544339
- Full Text :
- https://doi.org/10.1002/pbc.28010